Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Rater- and Subject-Blind, Parallel Group Trial to Investigate the Non-Inferiority of NT 201, Free of Complexing Proteins, in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

NCT00777803 is registered in ClinicalTrials.gov with Merz Pharmaceuticals GmbH as lead sponsor.

NCT NCT00777803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00777803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Rater- and Subject-Blind, Parallel Group Trial to Investigate the Non-Inferiority of NT 201, Free of Complexing Proteins, in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
Lead sponsor
Merz Pharmaceuticals GmbH
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
May 31, 2009
Enrollment
381 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines